Here’s Why You Don’t Bet Against This Dividend King

Markets person delivered plentifulness of twists lately, with ostentation cooling but maturation uneven and volatility inactive lurking astir each net corner. Smart investors cognize 1 information holds steady: reliable income beats hype each time.

That is wherefore you should see owning a healthcare elephantine that has raised its dividend done recessions, pandemics, and patent cliffs -- without missing a beat. Johnson & Johnson (NYSE:JNJ) is simply a Dividend King that doesn't conscionable pay; it delivers consistency that lets shareholders slumber soundly portion the broader marketplace twists.

Johnson & Johnson has hiked its dividend for 63 consecutive years, and stands poised to present its 64th yearly summation erstwhile it reports first-quarter 2026 net earlier the marketplace opens connected April 14. That way grounds isn't luck -- it's the effect of disciplined superior allocation crossed its diversified portfolio of medicines, aesculapian devices, and user wellness products.

Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement

Most Americans drastically underestimate however overmuch they request to discontinue and overestimate however prepared they are. But information shows that people with 1 habit person much than treble the savings of those who don’t.

Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, a near-5% increase. The banal present yields 2.14% astatine an annualized $5.20 per share. Over the past decade, it has delivered 5% compounded yearly growth. The payout ratio besides sits astatine a comfy 46.7%, leaving ample country for reinvestment oregon further hikes. In short, this isn't a high-yield trap—it's a instrumentality built for dependable raises for decades to come.